Persona
Curriculum Vitae
CURRICULUM VITAE
PROF. MARCO METRA
I. Personale
Data di nascita 13 Settembre 1957
Luogo di nascita Parma
II. Diplomi
1981 Laurea in Medicina, a pieni voti assoluti e lode presso l’Università di Parma
1985 Specialista in Cardiologia, presso l’Università di Parma
1989 Specialista in Medicina Interna, presso l’Università di Parma
III. Educazione
1978 - 1981 Interno presso l’Istituto di Cardiologia dell’Università di Parma
1982 - 1985 Specializzando presso l’Istituto di Cardiologia dell’Università di Brescia
1985 Visiting research associate, presso il Committee on Clinical Pharmacology, University of Chicago (Director, Leon I. Goldberg)
IV. Ruoli Accademici
Giugno 1986 - Ott. 2001 Ricercatore presso la Cattedra di Cardiologia dell’Università di Brescia
Dal 1 Nov. 2001 Professore Associato presso la Cattedra di Cardiologia dell’Università di Brescia
V. Ruoli Assistenziali
Dal 1/11/2012 Direttore dell’Unità Operativa Complessa di cardiologia. Spedali Civili di Brescia
24/6/2004 – 22/11/2004 Direttore pro-tempore della U.O. di Cardiologia della A.O. Spedali Civili di Brescia.
Dal 2003 Responsabile dell’Unità Operativa Semplice “Didattica e Scienza Applicata” dell’U.O. Complessa di Cardiologia degli Spedali Civili di Brescia
Dal 2/6/1986 Aiuto presso la Divisione di Cardiologia degli Spedali Civili di Brescia
VI. Attività Didattica
1996-99 Insegnamento di Angiologia nell’ambito del C.I. di Malattie dell’Apparato Cardiovascolare del Corso di Laurea in Medicina e Chirurgia dell’Università di Brescia
1999-2000 Insegnamento di Fisiopatologia Cardiovasculare nell’ambito del C.I. di Malattie dell’Apparato Cardiovascolare del Corso di Laurea in Medicina e Chirurgia dell’Università di Brescia
2000- Insegnamento di Cardiologia nell’ambito del C.I. di Malattie dell’Apparato Cardiovascolare del Corso di Laurea in Medicina e Chirurgia dell’Università di Brescia
1997- Insegnamento di Cardiologia presso il D.U. di Fisioterapia dell’Università di Brescia
2001- Insegnamento di Cardiologia nell’ambito del C.I. 16.V “Anestesia, sedazione e trattamento dell’emergenza” presso la Facoltà d’Odontoiatria dell’Università di Brescia
1990- Insegnamento di Fisiopatologia Clinica Cardiovascolare presso la Scuola di Specializzazione di Cardiologia dell’Università di Brescia
VII. Borse di studio
2011-14 Progetto MEDIA finanziato dalla Comunità Europea. Programma FP7. Co-investigatore
2010-4 Progetto BIOSTAT-CHF finanziato dalla Comunità Europea. Programma FP7. Ammontare totale 880.000 euro. Principale Investigator per l’Italia e responsabile internazionale del protocollo
1991-2001 Partecipante a ricerche finanziate dal Consiglio Nazionale delle Ricerche.
1986 Borsa di Studio del Ministero della Pubblica Istruzione per Attività di Ricerca presso Istituzioni Estere di livello Universitario.
VIII. Società Scientifiche d’Appartenenza
• Società Italiana di Cardiologia
• Heart Failure Association of the European Society of Cardiology (ex Working Group on Heart Failure of the European Society of Cardiology)
• Working group on exercise physiology, physiopathology and electrocardiography of the European Society of Cardiology
• Heart Failure Society of America
• American Heart Association Council on Circulation
IX. Ruoli svolti in Società Scientifiche
2010-12 e 2012-14: Membro eletto del Consiglio Direttivo della Società Italiana di cardiologia
Dal 2008: Fellow della Società Europea di Cardiologia
2008-2010 e 2010-2012: Membro del Congress Program Committee (CPC) della Società Europea di Cardiologia
Dal 2008 al 2010: Spokesperson per l’insufficienza cardiaca per il Press Committee della Società Europea di Cardiologia
Dal 2004: Membro dello Scientific Advisory Board della International Academy of Cardiology (Founder e Chairman, Asher Kimchi)
2006 Revisore scientifico per l’Agenzia Italiana del Farmaco (AIFA) per gli studi di farmacovigilanza e di appropriatezza di impiego dei farmaci
2004 - 2006 Membro del Comitato per le Linee Guida della Società Europea di Cardiologia
2004 - 2006 Segretario dell’Heart Failure Association of the European Society of Cardiology (Società per l’Insufficienza Cardiaca della Società Europea di Cardiologia).
Dal 2001 Membro del Consiglio Direttivo del Working Group on Heart Failure of the European Society of Cardiology (ora Heart Failure Association of the European Society of Cardiology)
1992-2000 Secretario della Sezione Lombarda della Società Italiana di Cardiologia
X. Ruoli nel Consiglio Direttivo di Ricerche Multicentriche
RELAX-AHF and RELAX-AHF-2: Co Chairman with Prof Teerlink, san francisco, CA
ASCEND-HF. Member of the Steering Committee and Chairman of the Concomitant therapy and device committee (Chairman: Robert Califf)
PROTECT-II. European Principal Investigator (Chairman: Barry Massie)
REACH-UP. European Principal Investigator (Chairman: Barry Massie)
VERITAS-2: Multicentre, double blind, randomized parallel group study to assess the efficacy, safety, and tolerability of tezosentan in patients with acute hearth failure. Membro del Comitato Direttivo.
EVEREST Trial. Membro of the Comitato per l’Assegnazione degli eventi Clinici (end-point committee).
COMET - MF 4455 (Carvedilol or Metoprolol European Trial) Membro del Comitato Durettivo (Presidente: Philip A Poole-Wilson, Londra).
MCC-135/GO1 A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability and safety of MCC-135 in subjects with chronic heart failure. NYHA class II/III. Membro del Comitato Direttivo.
My-026 ESSENTIAL The Studies of Oral Enoximone Therapy in Advanced Heart Chronic Heart Failure. Principale Investigatore.
PRIME III Study: Membro del Comitato Direttivo dello Studio Smith Kline & Beecham Worldwide Cardiovascular Advisory Board (President: Packer M, New York)
XI. Attività Editoriale
Dal 1 Gennaio 2015, Editor-in-Chief del European Journal of Heart failure, official journal of the Heart Failure Association of the European Society of Cardiology
Dal 1 Novembre 2012, Executive Editor del Journal of Cardiovascular Medicine, Official journal of the Italian Federation of Cardiology
Membro del Comitato Editoriale
– Cardiovascular Drugs and Therapy (impact factor nel 2006, 1.9))
– Heart failure Reviews (Impact factor nel 2006, 2.757)
– Clinical research in Cardiology (organo della Società Tedesca di Cardiologia, impact factor nel 2006, 1.35)
– European Journal of Heart Failure (impact factor nel 2006, 3.7)
– Journal of Cardiac Failure (impact factor nel 2006, 3.4))
– Minerva Cardioangiologica
– Heart International (Associate editor)
Attività di revisione
• The Lancet
• Circulation
• Journal of the American College of Cardiology
• European Heart Journal
• Heart
• European Journal on heart failure
• Journal of Cardiac Failure
• American Journal of Cardiology
• Italian heart journal
XII Attività scientifica
Principali aree di ricerca:
• Valutazione funzionale dei pazienti con insufficienza cardiaca
• Trattamento beta-bloccante nell’insufficienza cardiaca
• Ruolo dell’iperattività simpatica nell’insufficienza cardiaca
Pubblicazioni scientifiche
• Articoli originali in riviste scientifiche con revisore, n. 180
• Capitoli di libri e relazioni scientifiche n. 208
• Abstracts n. 408
• Impact factor (totale delle pubblicazioni) 483
SELEZIONE DELLE PUBBLICAZIONI SCIENTIFICHE
1. Kohli JD, Metra M, Satoh Y, Goldberg LI. Dopamine receptors in the stellate ganglion of the dog. Eur J Pharmacol. 1989; 164: 265-272.
2. Metra M, Raddino R, Dei Cas L, Visioli O. Assessment of peak oxygen consumption, lactate and ven¬tilatory thresholds and correlation with the resting and exercise hemodynamic data in chronic congestive heart failure. Am J Cardiol. 1990; 65: 1127-1133.
3. Metra M, Cannella G, La Canna G, Guaini T, Sandrini M, Gaggiotti M, Movilli E, Dei Cas L. Improvement in exercise capacity after correction of anemia in patients with end-stage renal failure. Am. J Cardiol. 1991; 68: 1060-1066.
4. Metra M, Dei Cas L, Panina G, Visioli O. Exercise hyperventilation chronic heart failure, and its relation to functional capacity and hemodynamics. Am J Cardiol. 1992; 70:622-8.
5. Leier CV, Dei Cas L, Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: Hyponatremia, hypokaliemia, and hypomagnesemia. Am Heart J. 1994; 128:564-74.
6. Mabee SW, Metra M, Reed DE, Dei Cas L, Cody RJ. Pulmonary hypertension and systemic hypotension as limitations to exercise in chronic heart failure. J Cardiac Failure. 1994; 1:27-33.
7. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994; 24:1678-87.
8. Metra M, Missale C, Spano PF, Dei Cas L. Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine. J Cardiovasc Pharmacol. 1995; 25:732-40.
9. Metra M, Dei Cas L. Role of exercise ventilation in the limitation of functional capacity of patients with congestive heart failure. Basic Res Cardiol. 1996; 91(Suppl. 1): 31-36.
10. Metra M, Nodari S, D’Aloia A, Madureri A, Rosselli F, Bontempi L, Zanini R, Dei Cas L. Effects of neurohumoral antagonism on symptoms and quality of life in heart failure. Eur Heart J. 1998; 19(Suppl B): B25 – B35.
11. Metra M, Nodari S, Raccagni D, Garbellini M, Boldi E, Bontempi L, Gaiti M, Dei Cas L. Maximal and submaximal exercise testing in heart failure. J Cardiovasc Pharmacol. 1998; 32(suppl 1):S36-S45.
12. Metra M, Faggiano P, D’Aloia A, Nodari S, Gualeni A, Raccagni D, Dei Cas L. Use of cardiopulmonary exercise testing with hemodynamic monitoring in the prognostic assessment of ambulatory patients with chronic heart failure. J Am Coll Cardiol. 1999; 33:943-50.
13. Metra M, Nodari S, D’Aloia A, Bontempi L, Boldi E, Dei Cas L. A rationale for the use of -blockers as standard treatment for heart failure. Am Heart J. 2000; 139: 511-21.
14. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L. Differential effects of -blockers in patients with heart failure. A prospective, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000; 102: 546-551.
15. Metra M, Nodari S, D'Aloia A, Muneretto C, Robertson AD, Bristow MR, Dei Cas L. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol. 2002;40:1248-58.
16. Poole-Wilson PA, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Metra M, J Remme W, Swedberg K, Torp-Pedersen C. Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. Eur J Heart Fail. 2002;4:321-9.
17. Metra M, Nodari S, Parrinello G, Giubbini R, Manca C, Dei Cas L. Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J. 2003;145:292-9.
18. Dei Cas L, Metra M, Nodari S, Dei Cas A, Gheorghiade M. Prevention and management of chronic heart failure in patients at risk.. Am J Cardiol. 2003;91(9A):10-7.
19. D'Aloia A, Faggiano P, Aurigemma G, Bontempi L, Ruggeri G, Metra M, Nodari S, Dei Cas L. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol. 2003;41:1805-11.
20. Poole-Wilson PA, Swedberg K, Cleland JGF, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A, for the COMET investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure. Results of the Carvedilol Or Metoprolol European Trial (COMET). Lancet 2003; 362:7-13.
21. Dell'Era P, Ronca R, Coco L, Nicoli S, Metra M, Presta M. Fibroblast growth factor receptor-1 is essential for in vitro cardiomyocyte development. Circ Res. 2003;93:414-20.
22. Nodari S, Metra M, Dei Cas L. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. Eur J Heart Fail. 2003;5:621-7. IF = 2.134
23. Nodari S, Metra M, Dei Cas A, Dei Cas L. Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. Eur J Heart Fail. 2003;5:803-9. IF=2.134
24. Cleland JG, Goode K, Erhardt L, Remme WJ, Charlesworth A, Poole-Wilson PA, Di Lenarda A, Hanrath P, Komajda M, Metra M, Swedberg K, Torp-Pedersen C, On Behalf Of The COMET Investigators. A Description of the Clinical Characteristics at Baseline of Patients Recruited into the Carvedilol or Metoprolol European Trial (COMET). Cardiovasc Drugs Ther. 2004;18:139-52. IF = 0.908
25. Covolo L, Gelatti U, Metra M, Nodari S, Picciche A, Pezzali N, Zani C, Alberti A, Donato F, Nardi G, Dei Cas L. Role of beta1- and beta2-adrenoceptor polymorphisms in heart failure: a case-control study. Eur Heart J. 2004;25:1534-41. IF = 6.131.
26. Metra M, Nodari S, Dei Cas L. Current guidelines in the pharmacological management of chronic heart failure. JRAAS 2004; 5(suppl 1): S11-S16.
27. Metra M, Cas LD, di Lenarda A, Poole-Wilson P. Beta-blockers in heart failure: are pharmacological differences clinically important? Heart Fail Rev. 2004;9:123-30.
28. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, Hasin Y, Lopez-Sendon J, Mebazaa A, Metra M, Rhodes A, Swedberg K, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie MR, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Garcia MA, Dickstein K, Albuquerque A, Conthe P, Crespo-Leiro M, Ferrari R, Follath F, Gavazzi A, Janssens U, Komajda M, Morais J, Moreno R, Singer M, Singh S, Tendera M, Thygesen K; ESC Committe for Practice Guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:384-416.
29. Torp-Pedersen C, Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lutiger B, Metra M, Remme WJ, Scherhag A, Skene A; COMET Investigators. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET. Am Heart J. 2005;149:370-6.
30. Swedberg K, Olsson LG, Charlesworth A, Cleland J, Hanrath P, Komajda M, Metra M, Torp-Pedersen C, Poole-Wilson P. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J. 2005; 26:1303-1308.
31. Ekman I, Cleland JG, Swedberg K, Charlesworth A, Metra M, Poole-Wilson PA. Symptoms in Patients With Heart Failure are Prognostic Predictors: Insights from COMET. J Card Fail. 2005;11:288-92.
32. Di Lenarda A, Remme WJ, Charlesworth A, Cleland JG, Lutiger B, Metra M, Komajda M, Torp-Pedersen C, Scherhag A, Swedberg K, Poole-Wilson PA; for the COMET investigators. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial). Eur J Heart Fail. 2005;7:640-9.
33. Metra M, Torp-Pedersen C, Swedberg K, Cleland JG, Di Lenarda A, Komajda M, Remme WJ, Lutiger B, Scherhag A, Lukas MA, Charlesworth A, Poole-Wilson PA. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J. 2005;26(21):2259-68. IF = 5.997.
34. Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005;96(6A):11G-17G. IF=2.327
35. Metra M, Zani C, Covolo L, Nodari S, Pezzali N, Gelatti U, Donato F, Nardi G, Dei Cas L. Role of beta1- and alpha2c-adrenergic receptor polymorphisms and their combination in heart failure: A case-control study. Eur J Heart Fail. 2005 2006; 8:131-5. IF = 3.546
36. Lowes BD, Shakar SF, Metra M, Feldman AM, Eichhorn E, Freytag JW, Gerber MJ, Liard JF, Hartman C, Gorczynski R, Evans G, Linseman JV, Stewart J, Robertson AD, Roecker EB, Demets DL, Bristow MR. Rationale and design of the enoximone clinical trials program. J Card Fail. 2005;11:659-69. IF=2.935
37. Metra M, Dei Cas L, Cleland JG. Pharmacokinetic and Pharmacodynamic Characteristics of beta-Blockers: When Differences May Matter. J Card Fail. 2006;12:177-81. IF=2.935
38. Cleland JG, Charlesworth A, Lubsen J, Swedberg K, Remme WJ, Erhardt L, Di Lenarda A, Komajda M, Metra M, Torp-Pedersen C, Poole-Wilson PA; COMET Investigators. A Comparison of the Effects of Carvedilol and Metoprolol on Well-Being, Morbidity, and Mortality (the "Patient Journey") in Patients With Heart Failure A Report From the Carvedilol Or Metoprolol European Trial (COMET). J Am Coll Cardiol. 2006;47:1603-11. IF=9.2
39. Metra M, Ponikowski P, Dickstein K, McMurray JJ, Gavazzi A, Bergh CH, Fraser AG, Jaarsma T, Pitsis A, Mohacsi P, Bohm M, Anker S, Dargie H, Brutsaert D, Komajda M; on behalf of the Heart Failure Association of the European Society of Cardiology. Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2007; 9:684-694. IF = 3.546
40. Metra M, Dei Cas L, Bristow MR. The pathophysiology of acute heart failure--it is a lot about fluid accumulation. Am Heart J. 2008;155:1-5. IF=3.514
41. Chiari E, Fracassi F, D'Aloia A, Vizzardi E, Zanini G, Rocca P, Metra M, Dei Cas. Right Ventricular Thrombus and Pulmonary Thromboembolism/Thrombosis in Behçet's Disease: A Case Report. J Am Soc Echocardiogr. 2008 Jan 14; [Epub ahead of print] IF = 1.427.
42. Cotter G, Metra M, Milo-Cotter O, Dittrich HC, Gheorghiade M. Fluid overload in acute heart failure - Re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail. 2008; 10:165-9. IF=3.242
43. Metra M, Nodari S, Parrinello G, Bordonali T, Bugatti S, Danesi R, Fontanella B, Lombardi C, Milani P, Verzura G, Cotter G, Dittrich H, Massie BM, Dei Cas L. Worsening renal function in patients hospitalised for acute heart failure: Clinical implications and prognostic significance. Eur J Heart Fail. 2008;10:188-95. IF=3.242
44. Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor CM, Metra M, Massie BM; Protect Steering Committee, Investigators, and Coordinators. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment.J Card Fail. 2008;14:631-40.
45. Allen LA, Metra M, Milo-Cotter O, Filippatos G, Reisin LH, Bensimhon DR, Gronda EG, Colombo P, Felker GM, Dei Cas L, Kremastinos DT, O'Connor CM, Cotter G, Davison BA, Dittrich HC, Velazquez EJ. Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of Measures of Disease Severity in Acute Heart Failure (MEASURE-AHF).J Card Fail. 2008;14:777-84.
Prof. Marco Metra.
PROF. MARCO METRA
I. Personale
Data di nascita 13 Settembre 1957
Luogo di nascita Parma
II. Diplomi
1981 Laurea in Medicina, a pieni voti assoluti e lode presso l’Università di Parma
1985 Specialista in Cardiologia, presso l’Università di Parma
1989 Specialista in Medicina Interna, presso l’Università di Parma
III. Educazione
1978 - 1981 Interno presso l’Istituto di Cardiologia dell’Università di Parma
1982 - 1985 Specializzando presso l’Istituto di Cardiologia dell’Università di Brescia
1985 Visiting research associate, presso il Committee on Clinical Pharmacology, University of Chicago (Director, Leon I. Goldberg)
IV. Ruoli Accademici
Giugno 1986 - Ott. 2001 Ricercatore presso la Cattedra di Cardiologia dell’Università di Brescia
Dal 1 Nov. 2001 Professore Associato presso la Cattedra di Cardiologia dell’Università di Brescia
V. Ruoli Assistenziali
Dal 1/11/2012 Direttore dell’Unità Operativa Complessa di cardiologia. Spedali Civili di Brescia
24/6/2004 – 22/11/2004 Direttore pro-tempore della U.O. di Cardiologia della A.O. Spedali Civili di Brescia.
Dal 2003 Responsabile dell’Unità Operativa Semplice “Didattica e Scienza Applicata” dell’U.O. Complessa di Cardiologia degli Spedali Civili di Brescia
Dal 2/6/1986 Aiuto presso la Divisione di Cardiologia degli Spedali Civili di Brescia
VI. Attività Didattica
1996-99 Insegnamento di Angiologia nell’ambito del C.I. di Malattie dell’Apparato Cardiovascolare del Corso di Laurea in Medicina e Chirurgia dell’Università di Brescia
1999-2000 Insegnamento di Fisiopatologia Cardiovasculare nell’ambito del C.I. di Malattie dell’Apparato Cardiovascolare del Corso di Laurea in Medicina e Chirurgia dell’Università di Brescia
2000- Insegnamento di Cardiologia nell’ambito del C.I. di Malattie dell’Apparato Cardiovascolare del Corso di Laurea in Medicina e Chirurgia dell’Università di Brescia
1997- Insegnamento di Cardiologia presso il D.U. di Fisioterapia dell’Università di Brescia
2001- Insegnamento di Cardiologia nell’ambito del C.I. 16.V “Anestesia, sedazione e trattamento dell’emergenza” presso la Facoltà d’Odontoiatria dell’Università di Brescia
1990- Insegnamento di Fisiopatologia Clinica Cardiovascolare presso la Scuola di Specializzazione di Cardiologia dell’Università di Brescia
VII. Borse di studio
2011-14 Progetto MEDIA finanziato dalla Comunità Europea. Programma FP7. Co-investigatore
2010-4 Progetto BIOSTAT-CHF finanziato dalla Comunità Europea. Programma FP7. Ammontare totale 880.000 euro. Principale Investigator per l’Italia e responsabile internazionale del protocollo
1991-2001 Partecipante a ricerche finanziate dal Consiglio Nazionale delle Ricerche.
1986 Borsa di Studio del Ministero della Pubblica Istruzione per Attività di Ricerca presso Istituzioni Estere di livello Universitario.
VIII. Società Scientifiche d’Appartenenza
• Società Italiana di Cardiologia
• Heart Failure Association of the European Society of Cardiology (ex Working Group on Heart Failure of the European Society of Cardiology)
• Working group on exercise physiology, physiopathology and electrocardiography of the European Society of Cardiology
• Heart Failure Society of America
• American Heart Association Council on Circulation
IX. Ruoli svolti in Società Scientifiche
2010-12 e 2012-14: Membro eletto del Consiglio Direttivo della Società Italiana di cardiologia
Dal 2008: Fellow della Società Europea di Cardiologia
2008-2010 e 2010-2012: Membro del Congress Program Committee (CPC) della Società Europea di Cardiologia
Dal 2008 al 2010: Spokesperson per l’insufficienza cardiaca per il Press Committee della Società Europea di Cardiologia
Dal 2004: Membro dello Scientific Advisory Board della International Academy of Cardiology (Founder e Chairman, Asher Kimchi)
2006 Revisore scientifico per l’Agenzia Italiana del Farmaco (AIFA) per gli studi di farmacovigilanza e di appropriatezza di impiego dei farmaci
2004 - 2006 Membro del Comitato per le Linee Guida della Società Europea di Cardiologia
2004 - 2006 Segretario dell’Heart Failure Association of the European Society of Cardiology (Società per l’Insufficienza Cardiaca della Società Europea di Cardiologia).
Dal 2001 Membro del Consiglio Direttivo del Working Group on Heart Failure of the European Society of Cardiology (ora Heart Failure Association of the European Society of Cardiology)
1992-2000 Secretario della Sezione Lombarda della Società Italiana di Cardiologia
X. Ruoli nel Consiglio Direttivo di Ricerche Multicentriche
RELAX-AHF and RELAX-AHF-2: Co Chairman with Prof Teerlink, san francisco, CA
ASCEND-HF. Member of the Steering Committee and Chairman of the Concomitant therapy and device committee (Chairman: Robert Califf)
PROTECT-II. European Principal Investigator (Chairman: Barry Massie)
REACH-UP. European Principal Investigator (Chairman: Barry Massie)
VERITAS-2: Multicentre, double blind, randomized parallel group study to assess the efficacy, safety, and tolerability of tezosentan in patients with acute hearth failure. Membro del Comitato Direttivo.
EVEREST Trial. Membro of the Comitato per l’Assegnazione degli eventi Clinici (end-point committee).
COMET - MF 4455 (Carvedilol or Metoprolol European Trial) Membro del Comitato Durettivo (Presidente: Philip A Poole-Wilson, Londra).
MCC-135/GO1 A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability and safety of MCC-135 in subjects with chronic heart failure. NYHA class II/III. Membro del Comitato Direttivo.
My-026 ESSENTIAL The Studies of Oral Enoximone Therapy in Advanced Heart Chronic Heart Failure. Principale Investigatore.
PRIME III Study: Membro del Comitato Direttivo dello Studio Smith Kline & Beecham Worldwide Cardiovascular Advisory Board (President: Packer M, New York)
XI. Attività Editoriale
Dal 1 Gennaio 2015, Editor-in-Chief del European Journal of Heart failure, official journal of the Heart Failure Association of the European Society of Cardiology
Dal 1 Novembre 2012, Executive Editor del Journal of Cardiovascular Medicine, Official journal of the Italian Federation of Cardiology
Membro del Comitato Editoriale
– Cardiovascular Drugs and Therapy (impact factor nel 2006, 1.9))
– Heart failure Reviews (Impact factor nel 2006, 2.757)
– Clinical research in Cardiology (organo della Società Tedesca di Cardiologia, impact factor nel 2006, 1.35)
– European Journal of Heart Failure (impact factor nel 2006, 3.7)
– Journal of Cardiac Failure (impact factor nel 2006, 3.4))
– Minerva Cardioangiologica
– Heart International (Associate editor)
Attività di revisione
• The Lancet
• Circulation
• Journal of the American College of Cardiology
• European Heart Journal
• Heart
• European Journal on heart failure
• Journal of Cardiac Failure
• American Journal of Cardiology
• Italian heart journal
XII Attività scientifica
Principali aree di ricerca:
• Valutazione funzionale dei pazienti con insufficienza cardiaca
• Trattamento beta-bloccante nell’insufficienza cardiaca
• Ruolo dell’iperattività simpatica nell’insufficienza cardiaca
Pubblicazioni scientifiche
• Articoli originali in riviste scientifiche con revisore, n. 180
• Capitoli di libri e relazioni scientifiche n. 208
• Abstracts n. 408
• Impact factor (totale delle pubblicazioni) 483
SELEZIONE DELLE PUBBLICAZIONI SCIENTIFICHE
1. Kohli JD, Metra M, Satoh Y, Goldberg LI. Dopamine receptors in the stellate ganglion of the dog. Eur J Pharmacol. 1989; 164: 265-272.
2. Metra M, Raddino R, Dei Cas L, Visioli O. Assessment of peak oxygen consumption, lactate and ven¬tilatory thresholds and correlation with the resting and exercise hemodynamic data in chronic congestive heart failure. Am J Cardiol. 1990; 65: 1127-1133.
3. Metra M, Cannella G, La Canna G, Guaini T, Sandrini M, Gaggiotti M, Movilli E, Dei Cas L. Improvement in exercise capacity after correction of anemia in patients with end-stage renal failure. Am. J Cardiol. 1991; 68: 1060-1066.
4. Metra M, Dei Cas L, Panina G, Visioli O. Exercise hyperventilation chronic heart failure, and its relation to functional capacity and hemodynamics. Am J Cardiol. 1992; 70:622-8.
5. Leier CV, Dei Cas L, Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: Hyponatremia, hypokaliemia, and hypomagnesemia. Am Heart J. 1994; 128:564-74.
6. Mabee SW, Metra M, Reed DE, Dei Cas L, Cody RJ. Pulmonary hypertension and systemic hypotension as limitations to exercise in chronic heart failure. J Cardiac Failure. 1994; 1:27-33.
7. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994; 24:1678-87.
8. Metra M, Missale C, Spano PF, Dei Cas L. Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine. J Cardiovasc Pharmacol. 1995; 25:732-40.
9. Metra M, Dei Cas L. Role of exercise ventilation in the limitation of functional capacity of patients with congestive heart failure. Basic Res Cardiol. 1996; 91(Suppl. 1): 31-36.
10. Metra M, Nodari S, D’Aloia A, Madureri A, Rosselli F, Bontempi L, Zanini R, Dei Cas L. Effects of neurohumoral antagonism on symptoms and quality of life in heart failure. Eur Heart J. 1998; 19(Suppl B): B25 – B35.
11. Metra M, Nodari S, Raccagni D, Garbellini M, Boldi E, Bontempi L, Gaiti M, Dei Cas L. Maximal and submaximal exercise testing in heart failure. J Cardiovasc Pharmacol. 1998; 32(suppl 1):S36-S45.
12. Metra M, Faggiano P, D’Aloia A, Nodari S, Gualeni A, Raccagni D, Dei Cas L. Use of cardiopulmonary exercise testing with hemodynamic monitoring in the prognostic assessment of ambulatory patients with chronic heart failure. J Am Coll Cardiol. 1999; 33:943-50.
13. Metra M, Nodari S, D’Aloia A, Bontempi L, Boldi E, Dei Cas L. A rationale for the use of -blockers as standard treatment for heart failure. Am Heart J. 2000; 139: 511-21.
14. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L. Differential effects of -blockers in patients with heart failure. A prospective, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000; 102: 546-551.
15. Metra M, Nodari S, D'Aloia A, Muneretto C, Robertson AD, Bristow MR, Dei Cas L. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol. 2002;40:1248-58.
16. Poole-Wilson PA, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Metra M, J Remme W, Swedberg K, Torp-Pedersen C. Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. Eur J Heart Fail. 2002;4:321-9.
17. Metra M, Nodari S, Parrinello G, Giubbini R, Manca C, Dei Cas L. Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J. 2003;145:292-9.
18. Dei Cas L, Metra M, Nodari S, Dei Cas A, Gheorghiade M. Prevention and management of chronic heart failure in patients at risk.. Am J Cardiol. 2003;91(9A):10-7.
19. D'Aloia A, Faggiano P, Aurigemma G, Bontempi L, Ruggeri G, Metra M, Nodari S, Dei Cas L. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol. 2003;41:1805-11.
20. Poole-Wilson PA, Swedberg K, Cleland JGF, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A, for the COMET investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure. Results of the Carvedilol Or Metoprolol European Trial (COMET). Lancet 2003; 362:7-13.
21. Dell'Era P, Ronca R, Coco L, Nicoli S, Metra M, Presta M. Fibroblast growth factor receptor-1 is essential for in vitro cardiomyocyte development. Circ Res. 2003;93:414-20.
22. Nodari S, Metra M, Dei Cas L. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. Eur J Heart Fail. 2003;5:621-7. IF = 2.134
23. Nodari S, Metra M, Dei Cas A, Dei Cas L. Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. Eur J Heart Fail. 2003;5:803-9. IF=2.134
24. Cleland JG, Goode K, Erhardt L, Remme WJ, Charlesworth A, Poole-Wilson PA, Di Lenarda A, Hanrath P, Komajda M, Metra M, Swedberg K, Torp-Pedersen C, On Behalf Of The COMET Investigators. A Description of the Clinical Characteristics at Baseline of Patients Recruited into the Carvedilol or Metoprolol European Trial (COMET). Cardiovasc Drugs Ther. 2004;18:139-52. IF = 0.908
25. Covolo L, Gelatti U, Metra M, Nodari S, Picciche A, Pezzali N, Zani C, Alberti A, Donato F, Nardi G, Dei Cas L. Role of beta1- and beta2-adrenoceptor polymorphisms in heart failure: a case-control study. Eur Heart J. 2004;25:1534-41. IF = 6.131.
26. Metra M, Nodari S, Dei Cas L. Current guidelines in the pharmacological management of chronic heart failure. JRAAS 2004; 5(suppl 1): S11-S16.
27. Metra M, Cas LD, di Lenarda A, Poole-Wilson P. Beta-blockers in heart failure: are pharmacological differences clinically important? Heart Fail Rev. 2004;9:123-30.
28. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, Hasin Y, Lopez-Sendon J, Mebazaa A, Metra M, Rhodes A, Swedberg K, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie MR, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Garcia MA, Dickstein K, Albuquerque A, Conthe P, Crespo-Leiro M, Ferrari R, Follath F, Gavazzi A, Janssens U, Komajda M, Morais J, Moreno R, Singer M, Singh S, Tendera M, Thygesen K; ESC Committe for Practice Guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:384-416.
29. Torp-Pedersen C, Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lutiger B, Metra M, Remme WJ, Scherhag A, Skene A; COMET Investigators. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET. Am Heart J. 2005;149:370-6.
30. Swedberg K, Olsson LG, Charlesworth A, Cleland J, Hanrath P, Komajda M, Metra M, Torp-Pedersen C, Poole-Wilson P. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J. 2005; 26:1303-1308.
31. Ekman I, Cleland JG, Swedberg K, Charlesworth A, Metra M, Poole-Wilson PA. Symptoms in Patients With Heart Failure are Prognostic Predictors: Insights from COMET. J Card Fail. 2005;11:288-92.
32. Di Lenarda A, Remme WJ, Charlesworth A, Cleland JG, Lutiger B, Metra M, Komajda M, Torp-Pedersen C, Scherhag A, Swedberg K, Poole-Wilson PA; for the COMET investigators. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial). Eur J Heart Fail. 2005;7:640-9.
33. Metra M, Torp-Pedersen C, Swedberg K, Cleland JG, Di Lenarda A, Komajda M, Remme WJ, Lutiger B, Scherhag A, Lukas MA, Charlesworth A, Poole-Wilson PA. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J. 2005;26(21):2259-68. IF = 5.997.
34. Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005;96(6A):11G-17G. IF=2.327
35. Metra M, Zani C, Covolo L, Nodari S, Pezzali N, Gelatti U, Donato F, Nardi G, Dei Cas L. Role of beta1- and alpha2c-adrenergic receptor polymorphisms and their combination in heart failure: A case-control study. Eur J Heart Fail. 2005 2006; 8:131-5. IF = 3.546
36. Lowes BD, Shakar SF, Metra M, Feldman AM, Eichhorn E, Freytag JW, Gerber MJ, Liard JF, Hartman C, Gorczynski R, Evans G, Linseman JV, Stewart J, Robertson AD, Roecker EB, Demets DL, Bristow MR. Rationale and design of the enoximone clinical trials program. J Card Fail. 2005;11:659-69. IF=2.935
37. Metra M, Dei Cas L, Cleland JG. Pharmacokinetic and Pharmacodynamic Characteristics of beta-Blockers: When Differences May Matter. J Card Fail. 2006;12:177-81. IF=2.935
38. Cleland JG, Charlesworth A, Lubsen J, Swedberg K, Remme WJ, Erhardt L, Di Lenarda A, Komajda M, Metra M, Torp-Pedersen C, Poole-Wilson PA; COMET Investigators. A Comparison of the Effects of Carvedilol and Metoprolol on Well-Being, Morbidity, and Mortality (the "Patient Journey") in Patients With Heart Failure A Report From the Carvedilol Or Metoprolol European Trial (COMET). J Am Coll Cardiol. 2006;47:1603-11. IF=9.2
39. Metra M, Ponikowski P, Dickstein K, McMurray JJ, Gavazzi A, Bergh CH, Fraser AG, Jaarsma T, Pitsis A, Mohacsi P, Bohm M, Anker S, Dargie H, Brutsaert D, Komajda M; on behalf of the Heart Failure Association of the European Society of Cardiology. Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2007; 9:684-694. IF = 3.546
40. Metra M, Dei Cas L, Bristow MR. The pathophysiology of acute heart failure--it is a lot about fluid accumulation. Am Heart J. 2008;155:1-5. IF=3.514
41. Chiari E, Fracassi F, D'Aloia A, Vizzardi E, Zanini G, Rocca P, Metra M, Dei Cas. Right Ventricular Thrombus and Pulmonary Thromboembolism/Thrombosis in Behçet's Disease: A Case Report. J Am Soc Echocardiogr. 2008 Jan 14; [Epub ahead of print] IF = 1.427.
42. Cotter G, Metra M, Milo-Cotter O, Dittrich HC, Gheorghiade M. Fluid overload in acute heart failure - Re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail. 2008; 10:165-9. IF=3.242
43. Metra M, Nodari S, Parrinello G, Bordonali T, Bugatti S, Danesi R, Fontanella B, Lombardi C, Milani P, Verzura G, Cotter G, Dittrich H, Massie BM, Dei Cas L. Worsening renal function in patients hospitalised for acute heart failure: Clinical implications and prognostic significance. Eur J Heart Fail. 2008;10:188-95. IF=3.242
44. Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor CM, Metra M, Massie BM; Protect Steering Committee, Investigators, and Coordinators. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment.J Card Fail. 2008;14:631-40.
45. Allen LA, Metra M, Milo-Cotter O, Filippatos G, Reisin LH, Bensimhon DR, Gronda EG, Colombo P, Felker GM, Dei Cas L, Kremastinos DT, O'Connor CM, Cotter G, Davison BA, Dittrich HC, Velazquez EJ. Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of Measures of Disease Severity in Acute Heart Failure (MEASURE-AHF).J Card Fail. 2008;14:777-84.
Prof. Marco Metra.